{"id":3046,"date":"2021-12-20T16:16:23","date_gmt":"2021-12-20T15:16:23","guid":{"rendered":"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/"},"modified":"2022-01-11T14:43:04","modified_gmt":"2022-01-11T13:43:04","slug":"clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2","status":"publish","type":"post","link":"https:\/\/www.croalliance.com\/en\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/","title":{"rendered":"Clinical phase completion of phase I trial with MAD0004J08 monoclonal antibody against SARS-CoV-2"},"content":{"rendered":"<p>December 2021 \u2013 <span style=\"color: #1565a2;\">CROss Alliance\u00ae<\/span> is glad to announce the completion of the clinical phase of CRO-20-144 trial with MAD0004J08, the monoclonal antibody developed by Fondazione Toscana Life Sciences (Italy) as a therapeutic agent against \u00a0SARS-CoV-2 infection.<\/p>\n<p>Thirty participants were enrolled in three different cohorts and received 3 ascending doses of the antibody at Centro Ricerche Cliniche Verona or at the Istituto Nazionale per le Malattie Infettive \u201cLazzaro Spallanzani\u201d in Rome. The 30<sup>th<\/sup> and last healthy volunteer of the phase I trial completed the last study visit on 20<sup>th<\/sup> October.<\/p>\n<p>Study data indicate an excellent tolerability and safety outcome (primary study objective). During the study the Data Monitoring Committee did not raise any concerns related to the antibody administration after each cohort completion. None of the subjects enrolled in the 3 cohorts had any serious adverse event in the first week after antibody intramuscular injection, nor during the six-month follow-up, when no SARS-CoV-2 infection was developed either.<\/p>\n<p>Final analysis is underway: in addition to the excellent safety profile the analysis has confirmed promising efficacy data with very good serum neutralisation power versus wild type (WT) virus and viral variants of concern (i.e., alpha, beta, gamma and delta).<\/p>\n<p>Final pharmacokinetic analysis is underway to describe the monoclonal antibody pharmacokinetic profile after one single intramuscular dose and confirm the expected long half-life which would allow the administration of a low dose maintaining at the same time a long-term action.<\/p>\n<p><span style=\"color: #1565a2;\">CROss Alliance\u00ae<\/span> is grateful to have been involved in the project management, regulatory, monitoring, analytical, data management, statistical and reporting activities of this trial with high relevance for the social community and world health in this period of still relevant pandemic effects.<\/p>\n<p>The company Toscana Life Sciences Sviluppo is the Sponsor of the study and is in charge of developing the therapy, currently in a phase II\/III clinical trial.<\/p>\n<p>TLS News (in Italian) at this link: <a href=\"http:\/\/www.toscanalifesciences.org\/it\/2021\/12\/completamento-dello-studio-clinico-di-fase-i-con-lanticorpo-monoclonale-mad0004j08-come-terapia-contro-linfezione-da-sars-cov-2\/\" target=\"_blank\" rel=\"noopener noreferrer\">Completamento dello studio clinico di fase I con l&#8217;anticorpo monoclonale MAD0004J08 come terapia contro l\u2019infezione da SARS-CoV-2 &#8211; Toscana Life Sciences<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>December 2021 \u2013 CROss Alliance\u00ae is glad to announce the completion of the clinical [&hellip;]<\/p>\n","protected":false},"author":4269,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-3046","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Clinical phase completion of phase I trial with MAD0004J08 monoclonal antibody against SARS-CoV-2 - CROss Alliance<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical phase completion of phase I trial with MAD0004J08 monoclonal antibody against SARS-CoV-2 - CROss Alliance\" \/>\n<meta property=\"og:description\" content=\"December 2021 \u2013 CROss Alliance\u00ae is glad to announce the completion of the clinical [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/\" \/>\n<meta property=\"og:site_name\" content=\"CROss Alliance\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-20T15:16:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-11T13:43:04+00:00\" \/>\n<meta name=\"author\" content=\"Cross_Editor\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Cross_Editor\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/\"},\"author\":{\"name\":\"Cross_Editor\",\"@id\":\"https:\/\/www.croalliance.com\/#\/schema\/person\/a4b02839b018a7d1b2dd9f3ce5f1c0dd\"},\"headline\":\"Clinical phase completion of phase I trial with MAD0004J08 monoclonal antibody against SARS-CoV-2\",\"datePublished\":\"2021-12-20T15:16:23+00:00\",\"dateModified\":\"2022-01-11T13:43:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/\"},\"wordCount\":351,\"publisher\":{\"@id\":\"https:\/\/www.croalliance.com\/#organization\"},\"articleSection\":[\"News Archive\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/\",\"url\":\"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/\",\"name\":\"Clinical phase completion of phase I trial with MAD0004J08 monoclonal antibody against SARS-CoV-2 - CROss Alliance\",\"isPartOf\":{\"@id\":\"https:\/\/www.croalliance.com\/#website\"},\"datePublished\":\"2021-12-20T15:16:23+00:00\",\"dateModified\":\"2022-01-11T13:43:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.croalliance.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinical phase completion of phase I trial with MAD0004J08 monoclonal antibody against SARS-CoV-2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.croalliance.com\/#website\",\"url\":\"https:\/\/www.croalliance.com\/\",\"name\":\"CROss Alliance\",\"description\":\"Contract Research Organization for Scientific Services\",\"publisher\":{\"@id\":\"https:\/\/www.croalliance.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.croalliance.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.croalliance.com\/#organization\",\"name\":\"CROss Alliance\",\"url\":\"https:\/\/www.croalliance.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.croalliance.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.croalliance.com\/wp-content\/uploads\/2018\/06\/logo.png\",\"contentUrl\":\"https:\/\/www.croalliance.com\/wp-content\/uploads\/2018\/06\/logo.png\",\"width\":300,\"height\":48,\"caption\":\"CROss Alliance\"},\"image\":{\"@id\":\"https:\/\/www.croalliance.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/cross-alliance\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.croalliance.com\/#\/schema\/person\/a4b02839b018a7d1b2dd9f3ce5f1c0dd\",\"name\":\"Cross_Editor\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical phase completion of phase I trial with MAD0004J08 monoclonal antibody against SARS-CoV-2 - CROss Alliance","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/","og_locale":"en_US","og_type":"article","og_title":"Clinical phase completion of phase I trial with MAD0004J08 monoclonal antibody against SARS-CoV-2 - CROss Alliance","og_description":"December 2021 \u2013 CROss Alliance\u00ae is glad to announce the completion of the clinical [&hellip;]","og_url":"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/","og_site_name":"CROss Alliance","article_published_time":"2021-12-20T15:16:23+00:00","article_modified_time":"2022-01-11T13:43:04+00:00","author":"Cross_Editor","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Cross_Editor","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/#article","isPartOf":{"@id":"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/"},"author":{"name":"Cross_Editor","@id":"https:\/\/www.croalliance.com\/#\/schema\/person\/a4b02839b018a7d1b2dd9f3ce5f1c0dd"},"headline":"Clinical phase completion of phase I trial with MAD0004J08 monoclonal antibody against SARS-CoV-2","datePublished":"2021-12-20T15:16:23+00:00","dateModified":"2022-01-11T13:43:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/"},"wordCount":351,"publisher":{"@id":"https:\/\/www.croalliance.com\/#organization"},"articleSection":["News Archive"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/","url":"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/","name":"Clinical phase completion of phase I trial with MAD0004J08 monoclonal antibody against SARS-CoV-2 - CROss Alliance","isPartOf":{"@id":"https:\/\/www.croalliance.com\/#website"},"datePublished":"2021-12-20T15:16:23+00:00","dateModified":"2022-01-11T13:43:04+00:00","breadcrumb":{"@id":"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.croalliance.com\/clinical-phase-completion-of-phase-i-trial-with-mad0004j08-monoclonal-antibody-against-sars-cov-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.croalliance.com\/"},{"@type":"ListItem","position":2,"name":"Clinical phase completion of phase I trial with MAD0004J08 monoclonal antibody against SARS-CoV-2"}]},{"@type":"WebSite","@id":"https:\/\/www.croalliance.com\/#website","url":"https:\/\/www.croalliance.com\/","name":"CROss Alliance","description":"Contract Research Organization for Scientific Services","publisher":{"@id":"https:\/\/www.croalliance.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.croalliance.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.croalliance.com\/#organization","name":"CROss Alliance","url":"https:\/\/www.croalliance.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.croalliance.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.croalliance.com\/wp-content\/uploads\/2018\/06\/logo.png","contentUrl":"https:\/\/www.croalliance.com\/wp-content\/uploads\/2018\/06\/logo.png","width":300,"height":48,"caption":"CROss Alliance"},"image":{"@id":"https:\/\/www.croalliance.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/cross-alliance"]},{"@type":"Person","@id":"https:\/\/www.croalliance.com\/#\/schema\/person\/a4b02839b018a7d1b2dd9f3ce5f1c0dd","name":"Cross_Editor"}]}},"_links":{"self":[{"href":"https:\/\/www.croalliance.com\/en\/wp-json\/wp\/v2\/posts\/3046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.croalliance.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.croalliance.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.croalliance.com\/en\/wp-json\/wp\/v2\/users\/4269"}],"replies":[{"embeddable":true,"href":"https:\/\/www.croalliance.com\/en\/wp-json\/wp\/v2\/comments?post=3046"}],"version-history":[{"count":0,"href":"https:\/\/www.croalliance.com\/en\/wp-json\/wp\/v2\/posts\/3046\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.croalliance.com\/en\/wp-json\/wp\/v2\/media?parent=3046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.croalliance.com\/en\/wp-json\/wp\/v2\/categories?post=3046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.croalliance.com\/en\/wp-json\/wp\/v2\/tags?post=3046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}